9-chloro-7-(2H-tetrazol-5-yl)chromeno[2,3-b]pyridin-5-one

Modify Date: 2024-01-29 11:10:42

9-chloro-7-(2H-tetrazol-5-yl)chromeno[2,3-b]pyridin-5-one Structure
9-chloro-7-(2H-tetrazol-5-yl)chromeno[2,3-b]pyridin-5-one structure
Common Name 9-chloro-7-(2H-tetrazol-5-yl)chromeno[2,3-b]pyridin-5-one
CAS Number 58712-69-9 Molecular Weight 299.67200
Density 1.645g/cm3 Boiling Point 607.5ºC at 760mmHg
Molecular Formula C13H6ClN5O2 Melting Point N/A
MSDS N/A Flash Point 321.2ºC

 Use of 9-chloro-7-(2H-tetrazol-5-yl)chromeno[2,3-b]pyridin-5-one


traxanox TFA is an orally available diuretic. traxanox TFA enhances phagocytosis of yeast granules by mouse peritoneal macrophages or rat peritoneal polymorphonuclear leukocytes in vitro. traxanox TFA restores inhibition of antibody production in BALB/c mice. traxanox TFA is also effective in restoring antibody production in BALB/c mice. traxanox TFA has been shown to enhance phagocytosis in BALB/c mice.

 Names

Name 9-chloro-7-(2H-tetrazol-5-yl)chromeno[2,3-b]pyridin-5-one
Synonym More Synonyms

  Biological Activity

Description traxanox TFA is an orally available diuretic. traxanox TFA enhances phagocytosis of yeast granules by mouse peritoneal macrophages or rat peritoneal polymorphonuclear leukocytes in vitro. traxanox TFA restores inhibition of antibody production in BALB/c mice. traxanox TFA is also effective in restoring antibody production in BALB/c mice. traxanox TFA has been shown to enhance phagocytosis in BALB/c mice.
In Vivo Traxanox TFA (100 mg/kg, p.o.) showed a tendency to suppress dextran edema and cotton pellet granuloma formation in adjuvant arthritis (AA) in rats. In experimental models of delayed-type hypersensitivity (DTH), Traxanox TFA (100 mg/kg, p.o.) inhibited the accumulation of the exudate and the leucocyte migration in B. pertussis-induced pleurisy in rats. Traxanox TFA (50 mg/kg) did not show any effect on AA in Lewis rats when administered orally for 21 days after the adjuvant inoculation, but the combined administration of Traxanox TFA with hydrocortisone (10 mg/kg, p.o.) or indomethacin (0.25 mg/kg, p.o.) resulted in a synergistic inhibition of AA. When the administration of Traxanox TFA was started 21 days before the adjuvant inoculation, it inhibited AA in a dose-dependent manner (50-100 mg/kg, p.o.). On the other hand, Traxanox TFA (100 mg/kg, p.o.) enhanced the concanavalin A-induced DTH-like skin reaction in guinea pigs. These results indicate that the mode of action of Traxanox TFA on inflammatory responses resembles that of D-penicillamine or levamisole, so it may prove to be clinically effective in treating rheumatoid arthritis.[1]
References 1. Terasawa M, et al. Effect of traxanox sodium on inflammatory response. Nihon Yakurigaku Zasshi. 1985 Nov;86(5):329-40. Japanese.

 Chemical & Physical Properties

Density 1.645g/cm3
Boiling Point 607.5ºC at 760mmHg
Molecular Formula C13H6ClN5O2
Molecular Weight 299.67200
Flash Point 321.2ºC
Exact Mass 299.02100
PSA 97.56000
LogP 2.17470
Index of Refraction 1.718

 Synonyms

Traxanox
Traxanoxum
Hot Compounds More...
Dichloromethane
CAS#:75-09-2
Polyacrylic acid
CAS#:9003-01-4
sodium carbonate
CAS#:497-19-8
Silicon dioxide
CAS#:7631-86-9
Triethanolamine
CAS#:102-71-6
Demeton
CAS#:126-75-0
Water
CAS#:7732-18-5
4-(4-Piperidinyl)morpholine dihydrochloride
CAS#:53617-35-9
Diclofenac sodium
CAS#:15307-79-6
Budesonide
CAS#:51372-29-3